Patterns of liver injury in COVID-19 - a German case series.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 27 6 2020
medline: 8 8 2020
entrez: 27 6 2020
Statut: ppublish

Résumé

Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current. We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany. At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and 22% experienced increasing aspartate aminotransferase and alanine aminotransferase, respectively, when transaminases were normal at admission. Severe liver injury defined by 3×> upper limit of normal was observed in 9.1% over a mean time of 10.5 days. Importantly, patients exhibited cytotoxicity including lactate dehydrogenase and creatinine kinase elevations, but no signs of relevant liver function impairment. In summary, in a case series of hospitalized patients in Germany, cytotoxicity in the absence of severe liver dysfunction at admission and only few cases suggestive of severe liver injury during hospital were observed.

Sections du résumé

BACKGROUND
Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current.
METHODS
We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany.
RESULTS
At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and 22% experienced increasing aspartate aminotransferase and alanine aminotransferase, respectively, when transaminases were normal at admission. Severe liver injury defined by 3×> upper limit of normal was observed in 9.1% over a mean time of 10.5 days. Importantly, patients exhibited cytotoxicity including lactate dehydrogenase and creatinine kinase elevations, but no signs of relevant liver function impairment.
CONCLUSION
In summary, in a case series of hospitalized patients in Germany, cytotoxicity in the absence of severe liver dysfunction at admission and only few cases suggestive of severe liver injury during hospital were observed.

Identifiants

pubmed: 32588791
doi: 10.1177/2050640620931657
pmc: PMC7435007
doi:

Substances chimiques

Antiviral Agents 0
Biomarkers 0
Aspartate Aminotransferases EC 2.6.1.1
Alanine Transaminase EC 2.6.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

814-819

Références

N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Dtsch Arztebl Int. 2020 Apr 17;117(16):271-278
pubmed: 32519944
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
J Hepatol. 2019 Apr;70(4):797-799
pubmed: 30635243
Nature. 2017 Jul 20;547(7663):350-354
pubmed: 28700576
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):503
pubmed: 28743983
Liver Int. 2009 Sep;29(8):1253-61
pubmed: 19040538
J Infect Dis. 2005 Jan 15;191(2):193-7
pubmed: 15609228
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Liver Int. 2019 May;39(5):812-814
pubmed: 31020772

Auteurs

Jörn M Schattenberg (JM)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.
Metabolic Liver Research Program, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Christian Labenz (C)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.
Metabolic Liver Research Program, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Marcus-Alexander Wörns (MA)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Philipp Menge (P)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Arndt Weinmann (A)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Peter R Galle (PR)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Martin F Sprinzl (MF)

Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH